Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Interest & Investment Income (2016 - 2025)

Celldex Therapeutics has reported Interest & Investment Income over the past 14 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $5.8 million for Q4 2025, down 34.68% from a year ago — trailing twelve months through Dec 2025 was $28.6 million (down 23.13% YoY), and the annual figure for FY2025 was $28.6 million, down 23.12%.
  • Interest & Investment Income for Q4 2025 was $5.8 million at Celldex Therapeutics, down from $6.6 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CLDX hit a ceiling of $10.5 million in Q2 2024 and a floor of $67000.0 in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $3.0 million (2023), compared with a mean of $4.1 million.
  • Biggest five-year swings in Interest & Investment Income: crashed 90.11% in 2021 and later skyrocketed 1402.42% in 2023.
  • Celldex Therapeutics' Interest & Investment Income stood at $192000.0 in 2021, then skyrocketed by 628.12% to $1.4 million in 2022, then skyrocketed by 209.08% to $4.3 million in 2023, then soared by 106.78% to $8.9 million in 2024, then tumbled by 34.68% to $5.8 million in 2025.
  • The last three reported values for Interest & Investment Income were $5.8 million (Q4 2025), $6.6 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.